<DOC>
	<DOCNO>NCT02015793</DOCNO>
	<brief_summary>The purpose study investigate efficacy , safety , pharmacokinetics adalimumab follow subcutaneous ( SC ) administration 2 dose regimen Chinese subject Crohn 's disease .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics , Safety Efficacy Two Treatment Modules Chinese Subjects With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Subjects Chinese descent full Chinese parentage . 2 . Diagnosis Crohn 's disease ( CD ) least 3 month prior Week 0 confirm endoscopy , radiologic evaluation , and/or histology Screening Period . 3 . Crohn 's Disease Activity Index ( CDAI ) ≥ 220 ≤ 450 despite treatment oral corticosteroid and/or immunosuppressant . 4 . Subject negative Tuberculosis ( TB ) Screening Assessment . 1 . Subject ulcerative colitis indeterminate colitis . 2 . Subject surgical bowel resection within past 6 month plan resection time point future . 3 . Subject ostomy ileoanal pouch . 4 . Subject short bowel syndrome . 5 . Subject symptomatic know obstructive stricture . 6 . Subject internal external fistula ( exception anal fistula without abscess ) . 7 . Chronic recur infection active TB .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>